![Roche obesity drug shows promise in early-stage trial](/content/images/size/w600/2024/07/6a03c9e6-4eab-481e-82b7-6d4058651cc9.png)
Health
Roche obesity drug shows promise in early-stage trial
Swiss pharmaceutical company Roche has reported positive results from its Phase I clinical trial of CT-996, a new drug being developed to treat obesity and type 2 diabetes. The once-daily oral small molecule GLP-1 receptor agonist demonstrated a placebo-adjusted mean weight loss of 6.1% within four weeks. The drug